Navigation Links
Freeze-Dried Formula May Block HIV Virus in Breast Milk
Date:7/3/2008

Could help prevent spread of disease in developing countries, study suggests,,

THURSDAY, July 2 (HealthDay News) -- In developing countries where breast-feeding is a necessity, and HIV is rampant, the risk of disease transmission through breast milk might be reduced if infants were first fed a freeze-dried formula full of good bacteria that could capture and potentially destroy the deadly virus.

But that hope is theoretical, because the formula hasn't been tested in humans. However, researchers from the University of Chicago report that they are one giant step closer to that reality, because they have designed a method that allows the good bacteria to remain active, even without refrigeration.

"The one major challenge for infant products going to Africa or other poor regions is that they don't have refrigeration, so anything you send has to be heat-resistant," explained one of the researchers, Lin Tao, an associate professor in the department of oral biology at the University of Illinois at Chicago.

Tao presented the findings Thursday at the International Association for Dental Research annual meeting, in Toronto.

Lactobacillus is a bacterium normally found in the mouth. It's one of the good bacteria found in some dairy products, such as yogurt or kefir. Surprisingly, this common bacteria has the ability to "capture" the HIV virus.

"HIV, though quite deadly as a disease, as a virus is relatively weak, so it's not surprising to find out that lactobacillus can act against HIV and maybe prevent its incorporation into mammalian cells," said Dr. Marc Siegel, an associate professor at the New York University School of Medicine and the author of False Alarm: The Truth About the Epidemic of Fear.

Tao and his colleague, Dr. R. Chang from Lavax, of Palatine, Ill., developed the new freeze-drying method for maintaining lactobacilli in a hot environment, and in the current study, they tested the new method at different temperatures to ensure that the lactobacilli remained viable.

Now that they've shown a method for keeping the bacteria alive in heat, the researchers have to decide the most effective product to use. Infant formula is an obvious candidate, or possibly a type of lollipop that an infant could suck on, Tao said.

Once the lactobacilli are ingested, the bacteria will colonize the infants' GI tract, and as long as they are fed milk, the bacteria will remain alive and able to capture HIV, said Tao.

"This study provides hope for the prevention of HIV. So far, all of the AIDS vaccines have failed in clinical trials, but this shows that there are alternatives. There are ways to conquer this virus," said Tao, who said the next step is to secure additional funding for further research.

"The notion of using probiotics to protect infants against HIV-positive breast milk is a novel, promising and interesting notion that bears further study," said Siegel.

More information

To learn more about HIV infection in babies and children, visit the National Institute of Allergy and Infectious Diseases.



SOURCES: Lin Tao, D.D.S., Ph.D., associate professor, department of oral biology, University of Illinois at Chicago; Marc Siegel, M.D., internist and associate professor, New York University Langone Medical Center and School of Medicine, and author, False Alarm: The Truth About the Epidemic of Fear; July 3, 2008, International Association for Dental Research annual meeting, Toronto


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Freeze-dried tendon implants prove effective in early studies
2. Termination of IS Clinical From Distributing PhytoCeuticals Formulas
3. Derma Sciences Launches Two New MEDIHONEY(TM) Formulations
4. MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
5. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
6. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
7. Wolters Kluwer Health Introduces Formulary Facts(TM), a Formulary Analytics Tool that Sets the Standard for Accuracy and Ease-of-Use
8. Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel
9. Formula Puts Doctor, Patient Glucose Readings on Same Page
10. PBM Companies Partner with the Red Cross to Donate Infant Formula to China Earthquake Victims
11. Study finds unique HIV vaccine formula elicits strong immune responses
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Freeze-Dried Formula May Block HIV Virus in Breast Milk
(Date:5/26/2016)... ... May 26, 2016 , ... ... of thousands of defective respirators, according to court documents and SEC filings. ... William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its ... partner for the Tamika Catchings Legacy Tour that will commemorate the Indiana ... hardwood basketball surfaces in all forms and levels of the game, Connor Sports has ...
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, ... biologics, consumer health and global clinical supply services, today announced two key appointments ... company’s continued investment and strategic growth plans in the Asia Pacific region. , ...
(Date:5/26/2016)... ... ... effort to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is ... the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of ... Mohebi says, “The positive response to the Snapchat videos we started last month has been ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... May 24, 2016 The ... world , s first dual therapy stent, ...   OrbusNeich, a global company specializing in ... portfolio to include products to treat peripheral artery disease. ... first entry devices for lower limb and arteriovenous (AV) ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
Breaking Medicine Technology: